DUOX1: A Potential Drug Target and Biomarker (G53905)

Target Name: DUOX1

NCBI ID: G53905

DUOX1

DUOX1: A Potential Drug Target and Biomarker

Duxorinib is an oral tablet that is currently in clinical trials for the treatment of hypertension, a common condition that affects millions of people worldwide. The drug is being developed by two companies, Sunovis and Targedal, and is being tested in a randomized, double-blind, placebo-controlled trial. In this article, we will discuss the potential drug target and biomarker for Duxorinib, as well as its potential impact on the treatment of hypertension.

The Importance of Duxorinib

Hypertension is a serious medical condition that can lead to a number of health problems, including heart disease, stroke, and heart failure. It is a leading cause of death in adults over the age of 65 and is a major contributor to disability in people of all ages. According to the World Health Organization (WHO), approximately 17.5% of adults worldwide have hypertension, and this number is expected to reach 22.6% by the year 2030.

Duxorinib is being developed as a potential drug target and biomarker for hypertension. The drug is designed to selectively inhibit the activity of a protein called TRPV4, which is a receptor on the surface of certain cells that plays a role in the regulation of blood pressure. By inhibiting TRPV4, Duxorinib is expected to reduce the pressure on the blood vessels, which can lead to a decrease in blood pressure and a reduction in the risk of hypertension-related complications.

Duxorinib's Potential Impact on the Treatment of Hypertension

Hypertension is a difficult condition to treat, and current treatments are often limited in their effectiveness. The development of Duxorinib is expected to provide a new treatment option for hypertension that is targeted specifically to this protein receptor. By inhibiting TRPV4, Duxorinib is expected to reduce the pressure on the blood vessels, which can lead to a decrease in blood pressure and a reduction in the risk of hypertension-related complications.

Duxorinib is also being tested for its potential impact on blood pressure in people with prehypertension, which is a condition in which a person's blood pressure is higher than normal but is not yet considered hypertension. Prehypertension is a common condition that can lead to a number of health problems, including heart disease and stroke. By treating prehypertension with Duxorinib, it is expected to reduce the risk of progression to hypertension and other related conditions.

The Development of Duxorinib

Duxorinib is being developed by Sunovis and Targedal for the treatment of hypertension and prehypertension. The drug is being tested in a randomized, double-blind, placebo-controlled trial, which is designed to compare the effects of Duxorinib to placebo in reducing blood pressure in people with prehypertension and hypertension.

The Benefits of Duxorinib

Duxorinib is expected to provide a number of potential benefits, including:

* Reduced blood pressure: Duxorinib is designed to selectively inhibit the activity of TRPV4, which is a receptor on the surface of certain cells that plays a role in the regulation of blood pressure. By inhibiting TRPV4, Duxorinib is expected to reduce the pressure on the blood vessels, which can lead to a decrease in blood pressure.
* Reduced risk of hypertension-related complications: hypertension can lead to a number of health problems, including heart disease, stroke, and heart failure. Duxorinib is expected to reduce the risk of these complications by reducing the

Protein Name: Dual Oxidase 1

Functions: Generates hydrogen peroxide which is required for the activity of thyroid peroxidase/TPO and lactoperoxidase/LPO. Plays a role in thyroid hormones synthesis and lactoperoxidase-mediated antimicrobial defense at the surface of mucosa. May have its own peroxidase activity through its N-terminal peroxidase-like domain

The "DUOX1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DUOX1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets